AstraZeneca announced a strategic collaboration and investment agreement with Cellectis, a leader in clinical-stage biotechnology. This partnership, valued initially at $105 million, signifies a substantial move in developing next-generation therapeutics, focusing on areas like oncology, immunology, and rare diseases, where medical needs remain high. Leveraging Gene Editing Technologies for Novel Therapies Under this agreement, AstraZeneca […]
Soliris (eculizumab), the first and only targeted therapy approved for the treatment of paediatric patients with refractory generalised myasthenia gravis (gMG), from Alexion, AstraZeneca Rare Disease has obtained approval for expanded use in the European Union (EU). The approval allows the treatment of gMG in children and adolescents aged six to 17 years who are […]
Alexion, a subdivision of AstraZeneca focusing on rare diseases, has announced its definitive purchase and licensing agreement for a portfolio of preclinical gene therapy programmes from Pfizer Inc. The deal, a move to strengthen Alexion and AstraZeneca’s commitment to next-generation genomic medicines, is worth up to $1 billion, plus tiered royalties on sales. This acquisition […]
Alexion, AstraZeneca Rare Disease has agreed to acquire LogicBio Therapeutics, an American clinical-stage genetic medicine company in a deal worth $68 million. As per the terms of the deal, shareholders of the NASDAQ-listed LogicBio Therapeutics will be paid $2.07 per share by Alexion, AstraZeneca Rare Disease. The latter was formed following last year’s $39 billion […]
